{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:38:58Z","timestamp":1791988738783,"version":"4.4.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Parkinson\u2019s disease (PD) is characterized by hypokinetic motor symptoms, tremor, and various non-motor symptoms with frequent fluctuations of symptoms in advanced disease stages. Invasive therapies, such as deep brain stimulation (DBS), ablative therapies, and continuous subcutaneous or intrajejunal delivery of dopaminergic drugs via pump therapies are available for the management of this complex motor symptomatology and may also impact non-motor symptoms. The recent update of the clinical guideline on PD by the German Neurological Society (Deutsche Gesellschaft f\u00fcr Neurologie e.V.; DGN) offers clear guidance on the indications and applications of these treatment options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The guideline committee formulated diagnostic questions for invasive therapies and structured them according to the PICOS framework (Population\u2013Intervention\u2013Comparisons\u2013Outcome\u2013Studies). A systematic literature review was conducted. Questions were addressed using the findings from the literature review and consented by the guideline committee.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Specific recommendations are given regarding (i) the optimal timing for starting invasive therapies, (ii) the application of DBS, (iii) the use of pump therapies in advanced PD, (iv) the indications for ablative procedures, and (iv) selecting the most appropriate therapy according to individual patient characteristics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This review is an adapted excerpt of the chapters on the use of invasive therapies in PD of the novel German guideline on PD. Clear recommendations on the use of treatment options for advanced PD are provided.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-12915-6","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:28:44Z","timestamp":1740223724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Invasive therapies for Parkinson\u2019s disease: an adapted excerpt from the guidelines of the German Society\u00a0of Neurology"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-1565","authenticated-orcid":false,"given":"Ren\u00e9","family":"Reese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Koeglsperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"T\u00f6nges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German Parkinson\u2018s Guideline Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"12915_CR1","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson disease. Nat Rev Dis Prim 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Prim"},{"key":"12915_CR2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mds.27386","volume":"33","author":"KR Chaudhuri","year":"2018","unstructured":"Chaudhuri KR, Poewe W, Brooks D (2018) Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord 33:909\u2013919. https:\/\/doi.org\/10.1002\/mds.27386","journal-title":"Mov Disord"},{"key":"12915_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/s0022-510x(99)00052-0","volume":"165","author":"AP Denny","year":"1999","unstructured":"Denny AP, Behari M (1999) Motor fluctuations in Parkinson\u2019s disease. J Neurol Sci 165:18\u201323. https:\/\/doi.org\/10.1016\/s0022-510x(99)00052-0","journal-title":"J Neurol Sci"},{"key":"12915_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O et al (2005) Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord 20:224\u2013230. https:\/\/doi.org\/10.1002\/mds.20279","journal-title":"Mov Disord"},{"key":"12915_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","volume":"20","author":"MC Hechtner","year":"2014","unstructured":"Hechtner MC, Vogt T, Z\u00f6llner Y et al (2014) Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries. Park Relat Disord 20:969\u2013974. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.06.001","journal-title":"Park Relat Disord"},{"key":"12915_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2011.01.003","volume":"17","author":"Y Winter","year":"2011","unstructured":"Winter Y, von Campenhausen S, Arend M et al (2011) Health-related quality of life and its determinants in Parkinson\u2019s disease: results of an Italian cohort study. Park Relat Disord 17:265\u2013269. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.003","journal-title":"Park Relat Disord"},{"key":"12915_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.21586","volume":"22","author":"P Martinez-Martin","year":"2007","unstructured":"Martinez-Martin P, Schapira AHV, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson\u2019s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623\u20131629. https:\/\/doi.org\/10.1002\/mds.21586","journal-title":"Mov Disord"},{"key":"12915_CR8","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1212\/wnl.47.5.1180","volume":"47","author":"ME Hillen","year":"1996","unstructured":"Hillen ME, Sage JI (1996) Nonmotor fluctuations in patients with Parkinson\u2019s disease. Neurology 47:1180\u20131183. https:\/\/doi.org\/10.1212\/wnl.47.5.1180","journal-title":"Neurology"},{"key":"12915_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1212\/wnl.59.3.408","volume":"59","author":"T Witjas","year":"2002","unstructured":"Witjas T, Kaphan E, Azulay JP et al (2002) Nonmotor fluctuations in Parkinson\u2019s disease. Neurology 59:408\u2013413. https:\/\/doi.org\/10.1212\/wnl.59.3.408","journal-title":"Neurology"},{"key":"12915_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2012.08.004","volume":"19","author":"M Seki","year":"2013","unstructured":"Seki M, Takahashi K, Uematsu D et al (2013) Clinical features and varieties of non-motor fluctuations in Parkinson\u2019s disease: a Japanese multicenter study. Park Relat Disord 19:104\u2013108. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.08.004","journal-title":"Park Relat Disord"},{"key":"12915_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/wnl.0b013e318285c0ed","volume":"80","author":"A Storch","year":"2013","unstructured":"Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease. Neurology 80:800\u2013809. https:\/\/doi.org\/10.1212\/wnl.0b013e318285c0ed","journal-title":"Neurology"},{"key":"12915_CR12","unstructured":"H\u00f6glinger G (2023) DGN S2k Leitlinie Parkinson-Krankheit"},{"key":"12915_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105514","volume":"116","author":"HH Fernandez","year":"2023","unstructured":"Fernandez HH, Odin P, Standaert DG et al (2023) Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson\u2019s disease continuum: revelations from the MANAGE-PD validation cohort. Park Relat Disord 116:105514. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105514","journal-title":"Park Relat Disord"},{"key":"12915_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1055\/a-0642-1737","volume":"45","author":"G Ebersbach","year":"2018","unstructured":"Ebersbach G, Poewe W (2018) \u201eMedikament\u00f6s ausbehandelte Fluktuationen\u201c trotz \u201eoptimierter peroraler\/transdermaler Therapie\u201c bei Morbus Parkinson: Versuch einer pragmatischen Definition. Aktuelle Neurol 45:665\u2013671. https:\/\/doi.org\/10.1055\/a-0642-1737","journal-title":"Aktuelle Neurol"},{"key":"12915_CR15","doi-asserted-by":"publisher","first-page":"4047392","DOI":"10.1155\/2017\/4047392","volume":"2017","author":"M-R Luquin","year":"2017","unstructured":"Luquin M-R, Kulisevsky J, Martinez-Martin P et al (2017) Consensus on the definition of advanced Parkinson\u2019s disease: a neurologists-based Delphi study (CEPA study). Park Dis 2017:4047392. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Park Dis"},{"key":"12915_CR16","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"key":"12915_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Chaudhuri KR, Slevin JT et al (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program. Parkinsonism Relat D 21:1133\u20131144. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.020","journal-title":"Parkinsonism Relat D"},{"key":"12915_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/nmt-2020-0021","volume":"10","author":"J Aldred","year":"2020","unstructured":"Aldred J, Anca-Herschkovitsch M, Antonini A et al (2020) Application of the \u20185-2-1\u2019 screening criteria in advanced Parkinson\u2019s disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag 10:309\u2013323. https:\/\/doi.org\/10.2217\/nmt-2020-0021","journal-title":"Neurodegener Dis Manag"},{"key":"12915_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/nejmoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355:896\u2013908. https:\/\/doi.org\/10.1056\/nejmoa060281","journal-title":"N Engl J Med"},{"key":"12915_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1212\/01.wnl.0000250253.03919.fb","volume":"68","author":"WMM Sch\u00fcpbach","year":"2007","unstructured":"Sch\u00fcpbach WMM, Malt\u00eate D, Houeto JL et al (2007) Neurosurgery at an earlier stage of Parkinson disease a randomized, controlled trial. Neurology 68:267\u2013271. https:\/\/doi.org\/10.1212\/01.wnl.0000250253.03919.fb","journal-title":"Neurology"},{"key":"12915_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63\u201373. https:\/\/doi.org\/10.1001\/jama.2008.929","journal-title":"JAMA"},{"key":"12915_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s1474-4422(10)70093-4","volume":"9","author":"A Williams","year":"2010","unstructured":"Williams A, Gill S, Varma T et al (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson\u2019s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9:581\u2013591. https:\/\/doi.org\/10.1016\/s1474-4422(10)70093-4","journal-title":"Lancet Neurol"},{"key":"12915_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/s1474-4422(11)70308-8","volume":"11","author":"MS Okun","year":"2012","unstructured":"Okun MS, Gallo BV, Mandybur G et al (2012) Subthalamic deep brain stimulation with a constant-current device in Parkinson\u2019s disease: an open-label randomised controlled trial. Lancet Neurol 11:140\u2013149. https:\/\/doi.org\/10.1016\/s1474-4422(11)70308-8","journal-title":"Lancet Neurol"},{"key":"12915_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/nejmoa1205158","volume":"368","author":"WMM Schuepbach","year":"2013","unstructured":"Schuepbach WMM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med 368:610\u2013622. https:\/\/doi.org\/10.1056\/nejmoa1205158","journal-title":"N Engl J Med"},{"key":"12915_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s1474-4422(20)30108-3","volume":"19","author":"JL Vitek","year":"2020","unstructured":"Vitek JL, Jain R, Chen L et al (2020) Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson\u2019s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurol 19:491\u2013501. https:\/\/doi.org\/10.1016\/s1474-4422(20)30108-3","journal-title":"Lancet Neurol"},{"key":"12915_CR26","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/nejmoa0907083","volume":"362","author":"KA Follett","year":"2010","unstructured":"Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 362:2077\u20132091. https:\/\/doi.org\/10.1056\/nejmoa0907083","journal-title":"N Engl J Med"},{"key":"12915_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s1474-4422(12)70264-8","volume":"12","author":"VJJ Odekerken","year":"2013","unstructured":"Odekerken VJJ, van Laar T, Staal MJ et al (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson\u2019s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12:37\u201344. https:\/\/doi.org\/10.1016\/s1474-4422(12)70264-8","journal-title":"Lancet Neurol"},{"key":"12915_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007037","author":"WMM Schuepbach","year":"2019","unstructured":"Schuepbach WMM, Tonder L, Schnitzler A et al (2019) Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000007037","journal-title":"Neurology"},{"key":"12915_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3171\/2018.12.jns182042","volume":"132","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Follett KA, Luo P et al (2020) Comparing two randomized deep brain stimulation trials for Parkinson\u2019s disease. J Neurosurg 132:1376\u20131384. https:\/\/doi.org\/10.3171\/2018.12.jns182042","journal-title":"J Neurosurg"},{"key":"12915_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/jnnp-2012-304396","volume":"84","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Duda JE, Carlson K et al (2013) Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson\u2019s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 84:1113. https:\/\/doi.org\/10.1136\/jnnp-2012-304396","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10072-020-04555-7","volume":"42","author":"Y Xu","year":"2021","unstructured":"Xu Y, Yang B, Zhou C et al (2021) Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson\u2019s disease: a systematic review and meta-analysis. Neurol Sci 42:267\u2013274. https:\/\/doi.org\/10.1007\/s10072-020-04555-7","journal-title":"Neurol Sci"},{"key":"12915_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T (2019) Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol 15:234\u2013242. https:\/\/doi.org\/10.1038\/s41582-019-0145-9","journal-title":"Nat Rev Neurol"},{"key":"12915_CR33","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1212\/wnl.0000000000012246","volume":"97","author":"F Bove","year":"2021","unstructured":"Bove F, Mulas D, Cavallieri F et al (2021) Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease. Neurology 97:e254\u2013e262. https:\/\/doi.org\/10.1212\/wnl.0000000000012246","journal-title":"Neurology"},{"key":"12915_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ana.20091","volume":"55","author":"J Volkmann","year":"2004","unstructured":"Volkmann J, Allert N, Voges J et al (2004) Long-term results of bilateral pallidal stimulation in Parkinson\u2019s disease. Ann Neurol 55:871\u2013875. https:\/\/doi.org\/10.1002\/ana.20091","journal-title":"Ann Neurol"},{"key":"12915_CR35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/mds.22735","volume":"25","author":"E Moro","year":"2010","unstructured":"Moro E, Lozano AM, Pollak P et al (2010) Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson\u2019s disease. Mov Disord 25:578\u2013586. https:\/\/doi.org\/10.1002\/mds.22735","journal-title":"Mov Disord"},{"key":"12915_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1212\/wnl.0b013e31825dcdc1","volume":"79","author":"FM Weaver","year":"2012","unstructured":"Weaver FM, Follett KA, Stern M et al (2012) Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 79:55\u201365. https:\/\/doi.org\/10.1212\/wnl.0b013e31825dcdc1","journal-title":"Neurology"},{"key":"12915_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1212\/wnl.0000000000002401","volume":"86","author":"VJJ Odekerken","year":"2016","unstructured":"Odekerken VJJ, Boel JA, Schmand BA et al (2016) GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology 86:755\u2013761. https:\/\/doi.org\/10.1212\/wnl.0000000000002401","journal-title":"Neurology"},{"key":"12915_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/jnnp.2007.118653","volume":"79","author":"MI Hariz","year":"2008","unstructured":"Hariz MI, Krack P, Alesch F et al (2008) Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry 79:694. https:\/\/doi.org\/10.1136\/jnnp.2007.118653","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ana.26302","volume":"91","author":"G Pal","year":"2022","unstructured":"Pal G, Mangone G, Hill EJ et al (2022) Parkinson disease and subthalamic nucleus deep brain stimulation: cognitive effects in GBA mutation carriers. Ann Neurol 91:424\u2013435. https:\/\/doi.org\/10.1002\/ana.26302","journal-title":"Ann Neurol"},{"key":"12915_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2023-332387","volume":"95","author":"M Avenali","year":"2024","unstructured":"Avenali M, Zangaglia R, Cuconato G et al (2024) Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry 95:309\u2013315. https:\/\/doi.org\/10.1136\/jnnp-2023-332387","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0140-6736(91)91175-T","volume":"337","author":"AL Benabid","year":"1991","unstructured":"Benabid AL, Pollak P, Gervason C et al (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337:403\u2013406","journal-title":"Lancet"},{"key":"12915_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/mds.870120312","volume":"12","author":"JP Hubble","year":"1997","unstructured":"Hubble JP, Busenbark KL, Wilkinson S et al (1997) Effects of thalamic deep brain stimulation based on tremor type and diagnosis. Mov Disord 12:337\u2013341. https:\/\/doi.org\/10.1002\/mds.870120312","journal-title":"Mov Disord"},{"key":"12915_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.410420304","volume":"42","author":"W Koller","year":"1997","unstructured":"Koller W, Pahwa R, Busenbark K et al (1997) High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 42:292\u2013299. https:\/\/doi.org\/10.1002\/ana.410420304","journal-title":"Ann Neurol"},{"key":"12915_CR44","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1212\/wnl.51.4.1063","volume":"51","author":"W Ondo","year":"1998","unstructured":"Ondo W, Jankovic J, Schwartz K et al (1998) Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson\u2019s disease tremor. Neurology 51:1063\u20131069. https:\/\/doi.org\/10.1212\/wnl.51.4.1063","journal-title":"Neurology"},{"key":"12915_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jnnp.66.3.289","volume":"66","author":"P Limousin","year":"1999","unstructured":"Limousin P, Speelman JD, Gielen F et al (1999) Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry 66:289\u2013296. https:\/\/doi.org\/10.1136\/jnnp.66.3.289","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR46","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/s1474-4422(13)70151-0","volume":"12","author":"G Deuschl","year":"2013","unstructured":"Deuschl G, Agid Y (2013) Subthalamic neurostimulation for Parkinson\u2019s disease with early fluctuations: balancing the risks and benefits. Lancet Neurol 12:1025\u20131034. https:\/\/doi.org\/10.1016\/s1474-4422(13)70151-0","journal-title":"Lancet Neurol"},{"key":"12915_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/b978-0-444-53497-2.00010-3","volume":"116","author":"G Deuschl","year":"2013","unstructured":"Deuschl G, Paschen S, Witt K (2013) Chapter 10 clinical outcome of deep brain stimulation for Parkinson\u2019s disease. Handb Clin Neurol 116:107\u2013128. https:\/\/doi.org\/10.1016\/b978-0-444-53497-2.00010-3","journal-title":"Handb Clin Neurol"},{"key":"12915_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/mds.10309","volume":"18","author":"S Rehncrona","year":"2003","unstructured":"Rehncrona S, Johnels B, Widner H et al (2003) Long-term efficacy of thalamic deep brain stimulation for tremor: double-blind assessments. Mov Disord 18:163\u2013170. https:\/\/doi.org\/10.1002\/mds.10309","journal-title":"Mov Disord"},{"key":"12915_CR49","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3171\/jns.2006.104.4.506","volume":"104","author":"R Pahwa","year":"2006","unstructured":"Pahwa R, Lyons KE, Wilkinson SB et al (2006) Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg 104:506\u2013512. https:\/\/doi.org\/10.3171\/jns.2006.104.4.506","journal-title":"J Neurosurg"},{"key":"12915_CR50","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/wnl.0000000000004295","volume":"89","author":"RG Cury","year":"2017","unstructured":"Cury RG, Fraix V, Castrioto A et al (2017) Thalamic deep brain stimulation for tremor in Parkinson disease, essential tremor, and dystonia. Neurology 89:1416\u20131423. https:\/\/doi.org\/10.1212\/wnl.0000000000004295","journal-title":"Neurology"},{"key":"12915_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2018.08.017","volume":"58","author":"JK Wong","year":"2019","unstructured":"Wong JK, Cauraugh JH, Ho KWD et al (2019) STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: a systematic review and meta-analysis. Park Relat Disord 58:56\u201362. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.08.017","journal-title":"Park Relat Disord"},{"key":"12915_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/ana.21596","volume":"65","author":"MS Okun","year":"2009","unstructured":"Okun MS, Fernandez HH, Wu SS et al (2009) Cognition and mood in Parkinson\u2019s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 65:586\u2013595. https:\/\/doi.org\/10.1002\/ana.21596","journal-title":"Ann Neurol"},{"key":"12915_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/archneur.62.4.554","volume":"62","author":"VC Anderson","year":"2005","unstructured":"Anderson VC, Burchiel KJ, Hogarth P et al (2005) Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol 62:554\u2013560. https:\/\/doi.org\/10.1001\/archneur.62.4.554","journal-title":"Arch Neurol"},{"key":"12915_CR54","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/nejmoa000827","volume":"345","author":"JA Obeso","year":"2001","unstructured":"Group D-BS for PDS, Obeso JA, Olanow CW et al (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson\u2019s disease. N Engl J Med 345:956\u2013963. https:\/\/doi.org\/10.1056\/nejmoa000827","journal-title":"N Engl J Med"},{"key":"12915_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/mds.28390","volume":"36","author":"TJC Zoon","year":"2021","unstructured":"Zoon TJC, Rooijen G, Balm GMFC et al (2021) Apathy induced by subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease: a meta-analysis. Mov Disord 36:317\u2013326. https:\/\/doi.org\/10.1002\/mds.28390","journal-title":"Mov Disord"},{"key":"12915_CR56","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00415-006-0177-0","volume":"253","author":"D Drapier","year":"2006","unstructured":"Drapier D, Drapier S, Sauleau P et al (2006) Does subthalamic nucleus stimulation induce apathy in Parkinson\u2019s disease? J Neurol 253:1083. https:\/\/doi.org\/10.1007\/s00415-006-0177-0","journal-title":"J Neurol"},{"key":"12915_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.848","volume":"7","author":"F Valldeoriola","year":"2017","unstructured":"Valldeoriola F, Santacruz P, R\u00edos J et al (2017) l-Dopa\/carbidopa intestinal gel and subthalamic nucleus stimulation: effects on cognition and behavior. Brain Behav 7:e00848. https:\/\/doi.org\/10.1002\/brb3.848","journal-title":"Brain Behav"},{"key":"12915_CR58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s1474-4422(18)30035-8","volume":"17","author":"E Lhomm\u00e9e","year":"2018","unstructured":"Lhomm\u00e9e E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, H\u00e4lbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-D\u00f6ring F, Kupsch A, Kr\u00fcger R, Elben S, Chabard\u00e8s S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Malt\u00eate D, Sauvaget A, Rau J, Schnitzler A, Sch\u00fcpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P, EARLYSTIM study group (2018) Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson\u2019s disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 17:223\u2013231. https:\/\/doi.org\/10.1016\/s1474-4422(18)30035-8","journal-title":"Lancet Neurol"},{"key":"12915_CR59","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/brain\/aws078","volume":"135","author":"E Lhomm\u00e9e","year":"2012","unstructured":"Lhomm\u00e9e E, Klinger H, Thobois S et al (2012) Subthalamic stimulation in Parkinson\u2019s disease: restoring the balance of motivated behaviours. Brain J Neurol 135:1463\u20131477. https:\/\/doi.org\/10.1093\/brain\/aws078","journal-title":"Brain J Neurol"},{"key":"12915_CR60","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","volume":"84","author":"A Eusebio","year":"2013","unstructured":"Eusebio A, Witjas T, Cohen J et al (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 84:868\u2013874. https:\/\/doi.org\/10.1136\/jnnp-2012-302387","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR61","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/mdc3.13738","volume":"10","author":"P Hernandez-Con","year":"2023","unstructured":"Hernandez-Con P, Lin I, Mamikonyan E et al (2023) Course of impulse control disorder symptoms in Parkinson\u2019s disease: deep brain stimulation versus medications. Mov Disord Clin Pr 10:903\u2013913. https:\/\/doi.org\/10.1002\/mdc3.13738","journal-title":"Mov Disord Clin Pr"},{"key":"12915_CR62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/jnnp-2019-322614","volume":"91","author":"ST Jost","year":"2020","unstructured":"Jost ST, Sauerbier A, Visser-Vandewalle V et al (2020) A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson\u2019s disease: results at the 36-month follow-up. J Neurol Neurosurg Psychiatry 91:687\u2013694. https:\/\/doi.org\/10.1136\/jnnp-2019-322614","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR63","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1212\/wnl.55.11.1732","volume":"55","author":"I Arnulf","year":"2000","unstructured":"Arnulf I, Bejjani BP, Garma L et al (2000) Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 55:1732\u20131735. https:\/\/doi.org\/10.1212\/wnl.55.11.1732","journal-title":"Neurology"},{"key":"12915_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mds.27626","volume":"34","author":"HS Dafsari","year":"2019","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A et al (2019) EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Mov Disord 34:353\u2013365. https:\/\/doi.org\/10.1002\/mds.27626","journal-title":"Mov Disord"},{"key":"12915_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221219","volume":"14","author":"J-H Choi","year":"2019","unstructured":"Choi J-H, Kim H-J, Lee J-Y et al (2019) Long-term effects of bilateral subthalamic nucleus stimulation on sleep in patients with Parkinson\u2019s disease. PLoS ONE 14:e0221219. https:\/\/doi.org\/10.1371\/journal.pone.0221219","journal-title":"PLoS ONE"},{"key":"12915_CR66","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1007\/s00415-020-09743-1","volume":"267","author":"HS Dafsari","year":"2020","unstructured":"Dafsari HS, Ray-Chaudhuri K, Ashkan K et al (2020) Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson\u2019s disease. J Neurol 267:1830\u20131841. https:\/\/doi.org\/10.1007\/s00415-020-09743-1","journal-title":"J Neurol"},{"key":"12915_CR67","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12883-022-02651-z","volume":"22","author":"F Zhang","year":"2022","unstructured":"Zhang F, Wang F, Li C-H et al (2022) Subthalamic nucleus-deep brain stimulation improves autonomic dysfunctions in Parkinson\u2019s disease. BMC Neurol 22:124. https:\/\/doi.org\/10.1186\/s12883-022-02651-z","journal-title":"BMC Neurol"},{"key":"12915_CR68","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/mds.27860","volume":"34","author":"P Krack","year":"2019","unstructured":"Krack P, Volkmann J, Tinkhauser G, Deuschl G (2019) Deep brain stimulation in movement disorders: from experimental surgery to evidence-based therapy. Mov Disord 34:1795\u20131810. https:\/\/doi.org\/10.1002\/mds.27860","journal-title":"Mov Disord"},{"key":"12915_CR69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759. https:\/\/doi.org\/10.1016\/s1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"12915_CR70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jnnp.2005.078659","volume":"77","author":"DD Gaspari","year":"2006","unstructured":"Gaspari DD, Siri C, Landi A et al (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson\u2019s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 77:450. https:\/\/doi.org\/10.1136\/jnnp.2005.078659","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mds.1276","volume":"17","author":"P Ka\u0148ovsk\u00fd","year":"2002","unstructured":"Ka\u0148ovsk\u00fd P, Kubov\u00e1 D, Bare\u0161 M et al (2002) Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 17:188\u2013191. https:\/\/doi.org\/10.1002\/mds.1276","journal-title":"Mov Disord"},{"key":"12915_CR72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3233\/jpd-2011-11037","volume":"1","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Reddy P, Antonini A et al (2011) Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson\u2019s disease compared to conventional therapy: a real life study of non motor effect. J Park Dis 1:197\u2013203. https:\/\/doi.org\/10.3233\/jpd-2011-11037","journal-title":"J Park Dis"},{"key":"12915_CR73","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord 30:510\u2013516. https:\/\/doi.org\/10.1002\/mds.26067","journal-title":"Mov Disord"},{"key":"12915_CR74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","volume":"65","author":"K Pietz","year":"1998","unstructured":"Pietz K, Hagell P, Odin P (1998) Subcutaneous apomorphine in late stage Parkinson\u2019s disease: a long term follow up. J Neurol Neurosurg Psychiatry 65:709. https:\/\/doi.org\/10.1136\/jnnp.65.5.709","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR75","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0140-6736(88)91193-2","volume":"331","author":"CMH Stibe","year":"1988","unstructured":"Stibe CMH, Kempster PA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 331:403\u2013406. https:\/\/doi.org\/10.1016\/s0140-6736(88)91193-2","journal-title":"Lancet"},{"key":"12915_CR76","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.parkreldis.2013.08.012","volume":"19","author":"A Todorova","year":"2013","unstructured":"Todorova A, Chaudhuri KR (2013) Subcutaneous apomorphine and non-motor symptoms in Parkinson\u2019s disease. Park Relat Disord 19:1073\u20131078. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.08.012","journal-title":"Park Relat Disord"},{"key":"12915_CR77","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2021) Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat D 83:79\u201385. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","journal-title":"Parkinsonism Relat D"},{"key":"12915_CR78","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17949","volume":"13","author":"S Gaire","year":"2021","unstructured":"Gaire S, Kafle S, Bastakoti S et al (2021) Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: a systematic review. Cureus 13:e17949. https:\/\/doi.org\/10.7759\/cureus.17949","journal-title":"Cureus"},{"key":"12915_CR79","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager R, Hughes A, Evans A et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov Disord 20:151\u2013157. https:\/\/doi.org\/10.1002\/mds.20276","journal-title":"Mov Disord"},{"key":"12915_CR80","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","volume":"40","author":"E Olivola","year":"2019","unstructured":"Olivola E, Fasano A, Varanese S et al (2019) Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci 40:1917\u20131923. https:\/\/doi.org\/10.1007\/s10072-019-03920-5","journal-title":"Neurol Sci"},{"key":"12915_CR81","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","volume":"258","author":"A Antonini","year":"2011","unstructured":"Antonini A, Isaias IU, Rodolfi G et al (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258:579\u2013585. https:\/\/doi.org\/10.1007\/s00415-010-5793-z","journal-title":"J Neurol"},{"key":"12915_CR82","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.wnl.0000149637.70961.4c","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Remahl AIMN, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216\u2013223. https:\/\/doi.org\/10.1212\/01.wnl.0000149637.70961.4c","journal-title":"Neurology"},{"key":"12915_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/cer.14.33","volume":"3","author":"LN Guthikonda","year":"2014","unstructured":"Guthikonda LN, Lyons KE, Pahwa R (2014) Continuous infusion of levodopa\u2013carbidopa intestinal gel in Parkinson\u2019s disease. J Comp Effect Res 3:331\u2013333. https:\/\/doi.org\/10.2217\/cer.14.33","journal-title":"J Comp Effect Res"},{"key":"12915_CR84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1474-4422(13)70293-x","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa\u2013carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149. https:\/\/doi.org\/10.1016\/s1474-4422(13)70293-x","journal-title":"Lancet Neurol"},{"key":"12915_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Park Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Park Relat Disord"},{"key":"12915_CR86","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s10072-020-04401-w","volume":"41","author":"A Antonini","year":"2020","unstructured":"Antonini A, Marano P, Gusmaroli G et al (2020) Long-term effectiveness of levodopa\u2013carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson\u2019s disease: results of the Italian GLORIA patient population. Neurol Sci 41:2929\u20132937. https:\/\/doi.org\/10.1007\/s10072-020-04401-w","journal-title":"Neurol Sci"},{"key":"12915_CR87","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000442151","volume":"74","author":"S Bohlega","year":"2016","unstructured":"Bohlega S, Al-Shaar HA, Alkhairallah T et al (2016) Levodopa\u2013carbidopa intestinal gel infusion therapy in advanced Parkinson\u2019s disease: single middle eastern center experience. Eur Neurol 74:227\u2013236. https:\/\/doi.org\/10.1159\/000442151","journal-title":"Eur Neurol"},{"key":"12915_CR88","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","volume":"21","author":"M Buongiorno","year":"2015","unstructured":"Buongiorno M, Antonelli F, C\u00e1mara A et al (2015) Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Park Relat Disord 21:871\u2013876. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.05.014","journal-title":"Park Relat Disord"},{"key":"12915_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/wnf.0b013e31814b113e","volume":"31","author":"K Eggert","year":"2008","unstructured":"Eggert K, Schrader C, Hahn M et al (2008) Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151\u2013166. https:\/\/doi.org\/10.1097\/wnf.0b013e31814b113e","journal-title":"Clin Neuropharmacol"},{"key":"12915_CR90","first-page":"79","volume":"16","author":"A Fasano","year":"2012","unstructured":"Fasano A, Ricciardi L, Lena F et al (2012) Intrajejunal levodopa infusion in advanced Parkinson\u2019s disease: long-term effects on motor and non-motor symptoms and impact on patient\u2019s and caregiver\u2019s quality of life. Eur Rev Med Pharmacol 16:79\u201389","journal-title":"Eur Rev Med Pharmacol"},{"key":"12915_CR91","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord 30:500\u2013509. https:\/\/doi.org\/10.1002\/mds.26123","journal-title":"Mov Disord"},{"key":"12915_CR92","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/362908","volume":"2013","author":"T Foltynie","year":"2013","unstructured":"Foltynie T, Magee C, James C et al (2013) Impact of duodopa on quality of life in advanced parkinson\u2019s disease: a UK case series. Park\u2019s Dis 2013:362908. https:\/\/doi.org\/10.1155\/2013\/362908","journal-title":"Park\u2019s Dis"},{"key":"12915_CR93","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468\u20131474. https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"key":"12915_CR94","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/mds.23524","volume":"26","author":"A Merola","year":"2011","unstructured":"Merola A, Zibetti M, Angrisano S et al (2011) Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson\u2019s disease. Mov Disord 26:664\u2013670. https:\/\/doi.org\/10.1002\/mds.23524","journal-title":"Mov Disord"},{"key":"12915_CR95","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/j.1600-0404.2012.01689.x","volume":"126","author":"SE P\u00e5lhagen","year":"2012","unstructured":"P\u00e5lhagen SE, Dizdar N, Hauge T et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126:e29\u2013e33. https:\/\/doi.org\/10.1111\/j.1600-0404.2012.01689.x","journal-title":"Acta Neurol Scand"},{"key":"12915_CR96","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/wnf.0b013e3182613dea","volume":"35","author":"P Reddy","year":"2012","unstructured":"Reddy P, Martinez-Martin P, Rizos A et al (2012) Intrajejunal levodopa versus conventional therapy in Parkinson disease. Clin Neuropharmacol 35:205\u2013207. https:\/\/doi.org\/10.1097\/wnf.0b013e3182613dea","journal-title":"Clin Neuropharmacol"},{"key":"12915_CR97","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00702-013-1153-3","volume":"121","author":"M Sensi","year":"2014","unstructured":"Sensi M, Preda F, Trevisani L et al (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm 121:633\u2013642. https:\/\/doi.org\/10.1007\/s00702-013-1153-3","journal-title":"J Neural Transm"},{"key":"12915_CR98","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/jpd-191605","volume":"9","author":"W Poewe","year":"2019","unstructured":"Poewe W, Bergmann L, Kukreja P et al (2019) Levodopa\u2013carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Park Dis 9:531\u2013541. https:\/\/doi.org\/10.3233\/jpd-191605","journal-title":"J Park Dis"},{"key":"12915_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2408","volume":"11","author":"KAM Pauls","year":"2021","unstructured":"Pauls KAM, Toppila J, Koivu M et al (2021) Polyneuropathy monitoring in Parkinson\u2019s disease patients treated with levodopa\/carbidopa intestinal gel. Brain Behav 11:e2408. https:\/\/doi.org\/10.1002\/brb3.2408","journal-title":"Brain Behav"},{"key":"12915_CR100","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1017\/cjn.2021.78","volume":"49","author":"J Taher","year":"2022","unstructured":"Taher J, Naranian T, Poon Y-Y et al (2022) Vitamins and infusion of levodopa\u2013carbidopa intestinal gel. Can J Neurol Sci J Can des Sci Neurol 49:19\u201328. https:\/\/doi.org\/10.1017\/cjn.2021.78","journal-title":"Can J Neurol Sci J Can des Sci Neurol"},{"key":"12915_CR101","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","volume":"19","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, van Laar T, Cornblath DR et al (2013) Peripheral neuropathy in Parkinson\u2019s disease: levodopa exposure and implications for duodenal delivery. Park Relat Disord 19:501\u2013507. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.006","journal-title":"Park Relat Disord"},{"key":"12915_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.698","volume":"7","author":"S Loens","year":"2017","unstructured":"Loens S, Chorbadzhieva E, Kleimann A et al (2017) Effects of levodopa\/carbidopa intestinal gel versus oral levodopa\/carbidopa on B vitamin levels and neuropathy. Brain Behav 7:e00698. https:\/\/doi.org\/10.1002\/brb3.698","journal-title":"Brain Behav"},{"key":"12915_CR103","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00415-013-7235-1","volume":"261","author":"MT C\u00e1ceres-Redondo","year":"2014","unstructured":"C\u00e1ceres-Redondo MT, Carrillo F, Lama MJ et al (2014) Long-term levodopa\/carbidopa intestinal gel in advanced Parkinson\u2019s disease. J Neurol 261:561\u2013569. https:\/\/doi.org\/10.1007\/s00415-013-7235-1","journal-title":"J Neurol"},{"key":"12915_CR104","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.parkreldis.2014.12.012","volume":"21","author":"A Antonini","year":"2015","unstructured":"Antonini A, Yegin A, Preda C et al (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa\u2013carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism Relat D 21:231\u2013235. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.012","journal-title":"Parkinsonism Relat D"},{"key":"12915_CR105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11910-020-01062-2","volume":"20","author":"N Prakash","year":"2020","unstructured":"Prakash N, Simuni T (2020) Infusion therapies for Parkinson\u2019s disease. Curr Neurol Neurosci Rep 20:44. https:\/\/doi.org\/10.1007\/s11910-020-01062-2","journal-title":"Curr Neurol Neurosci Rep"},{"key":"12915_CR106","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R et al (2021) The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther 38:2854\u20132890. https:\/\/doi.org\/10.1007\/s12325-021-01747-1","journal-title":"Adv Ther"},{"key":"12915_CR107","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/ene.13847","volume":"26","author":"KR Chaudhuri","year":"2019","unstructured":"Chaudhuri KR, Antonini A, Robieson WZ et al (2019) Burden of non-motor symptoms in Parkinson\u2019s disease patients predicts improvement in quality of life during treatment with levodopa\u2013carbidopa intestinal gel. Eur J Neurol 26:581-e43. https:\/\/doi.org\/10.1111\/ene.13847","journal-title":"Eur J Neurol"},{"key":"12915_CR108","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/jpd-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C et al (2015) Long-term safety and maintenance of efficacy of levodopa\u2013carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Park\u2019s Dis 5:165\u201374. https:\/\/doi.org\/10.3233\/jpd-140456","journal-title":"J Park\u2019s Dis"},{"key":"12915_CR109","doi-asserted-by":"publisher","first-page":"175628642211080","DOI":"10.1177\/17562864221108018","volume":"15","author":"D Nyholm","year":"2022","unstructured":"Nyholm D, Jost WH (2022) Levodopa\u2013entacapone\u2013carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance. Ther Adv Neurol Disord 15:17562864221108018. https:\/\/doi.org\/10.1177\/17562864221108018","journal-title":"Ther Adv Neurol Disord"},{"key":"12915_CR110","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/ene.12309","volume":"21","author":"M Zibetti","year":"2014","unstructured":"Zibetti M, Merola A, Artusi CA et al (2014) Levodopa\/carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: a 7-year experience. Eur J Neurol 21:312\u2013318. https:\/\/doi.org\/10.1111\/ene.12309","journal-title":"Eur J Neurol"},{"key":"12915_CR111","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mdc3.13361","volume":"9","author":"V Viljaharju","year":"2022","unstructured":"Viljaharju V, Mertsalmi T, Pauls KAM et al (2022) Single-center study of 103 consecutive Parkinson\u2019s disease patients with levodopa\u2013carbidopa intestinal gel. Mov Disord Clin Pract 9:60\u201368. https:\/\/doi.org\/10.1002\/mdc3.13361","journal-title":"Mov Disord Clin Pract"},{"key":"12915_CR112","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.parkreldis.2017.02.020","volume":"38","author":"M Sensi","year":"2017","unstructured":"Sensi M, Cossu G, Mancini F et al (2017) Which patients discontinue? Issues on levodopa\/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Park Relat Disord 38:90\u201392. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.020","journal-title":"Park Relat Disord"},{"key":"12915_CR113","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","volume":"15","author":"AM Lozano","year":"2019","unstructured":"Lozano AM, Lipsman N, Bergman H et al (2019) Deep brain stimulation: current challenges and future directions. Nat Rev Neurol 15:148\u2013160. https:\/\/doi.org\/10.1038\/s41582-018-0128-2","journal-title":"Nat Rev Neurol"},{"key":"12915_CR114","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/mds.26625","volume":"32","author":"Y Higuchi","year":"2017","unstructured":"Higuchi Y, Matsuda S, Serizawa T (2017) Gamma knife radiosurgery in movement disorders: indications and limitations. Mov Disord 32:28\u201335. https:\/\/doi.org\/10.1002\/mds.26625","journal-title":"Mov Disord"},{"key":"12915_CR115","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1227\/neu.0b013e3182350893","volume":"70","author":"C Ohye","year":"2012","unstructured":"Ohye C, Higuchi Y, Shibazaki T et al (2012) Gamma knife thalamotomy for Parkinson disease and essential tremor: a prospective multicenter study. Neurosurgery 70:526\u201335. https:\/\/doi.org\/10.1227\/neu.0b013e3182350893. (discussion 535\u20136)","journal-title":"Neurosurgery"},{"key":"12915_CR116","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1001\/archneur.58.12.1995","volume":"58","author":"MS Okun","year":"2001","unstructured":"Okun MS, Stover NP, Subramanian T et al (2001) Complications of gamma knife surgery for Parkinson disease. Arch Neurol Chicago 58:1995\u20132002. https:\/\/doi.org\/10.1001\/archneur.58.12.1995","journal-title":"Arch Neurol Chicago"},{"key":"12915_CR117","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3171\/jns.2005.103.6.0956","volume":"103","author":"F Weaver","year":"2005","unstructured":"Weaver F, Follett K, Hur K et al (2005) Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg 103:956\u2013967. https:\/\/doi.org\/10.3171\/jns.2005.103.6.0956","journal-title":"J Neurosurg"},{"key":"12915_CR118","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/s0140-6736(99)03556-4","volume":"354","author":"RM de Bie","year":"1999","unstructured":"de Bie RM, de Haan RJ, Nijssen PC et al (1999) Unilateral pallidotomy in Parkinson\u2019s disease: a randomised, single-blind, multicentre trial. Lancet 354:1665\u20131669. https:\/\/doi.org\/10.1016\/s0140-6736(99)03556-4","journal-title":"Lancet"},{"key":"12915_CR119","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/ana.10517","volume":"53","author":"JL Vitek","year":"2003","unstructured":"Vitek JL, Bakay RAE, Freeman A et al (2003) Randomized trial of pallidotomy versus medical therapy for Parkinson\u2019s disease. Ann Neurol 53:558\u2013569. https:\/\/doi.org\/10.1002\/ana.10517","journal-title":"Ann Neurol"},{"key":"12915_CR120","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"AE Bond","year":"2017","unstructured":"Bond AE, Shah BB, Huss DS et al (2017) Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol 74:1412. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3098","journal-title":"JAMA Neurol"},{"key":"12915_CR121","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jamaneurol.2018.0263","volume":"75","author":"I Schlesinger","year":"2018","unstructured":"Schlesinger I, Sinai A, Zaaroor M (2018) Assessing tremor and adverse events in patients with tremor-dominant Parkinson disease undergoing focused ultrasound thalamotomy. JAMA Neurol 75:632. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0263","journal-title":"JAMA Neurol"},{"key":"12915_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3346\/jkms.2018.33.e279","volume":"33","author":"NY Jung","year":"2018","unstructured":"Jung NY, Chang JW (2018) Magnetic resonance-guided focused ultrasound in neurosurgery: taking lessons from the past to inform the future. J Korean Med Sci 33:1\u201316. https:\/\/doi.org\/10.3346\/jkms.2018.33.e279","journal-title":"J Korean Med Sci"},{"key":"12915_CR123","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1056\/nejmoa2016311","volume":"383","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2020","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, M\u00e1\u00f1ez-Mir\u00f3 JU, Rodr\u00edguez-Rojas R et al (2020) Randomized trial of focused ultrasound subthalamotomy for Parkinson\u2019s disease. N Engl J Med 383:2501\u20132513. https:\/\/doi.org\/10.1056\/nejmoa2016311","journal-title":"N Engl J Med"},{"key":"12915_CR124","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/nejmoa2202721","volume":"388","author":"V Krishna","year":"2023","unstructured":"Krishna V, Fishman PS, Eisenberg HM et al (2023) Trial of globus pallidus focused ultrasound ablation in Parkinson\u2019s disease. New Engl J Med 388:683\u2013693. https:\/\/doi.org\/10.1056\/nejmoa2202721","journal-title":"New Engl J Med"},{"key":"12915_CR125","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/jnnp-2020-323656","volume":"92","author":"F Lin","year":"2021","unstructured":"Lin F, Wu D, Yu J et al (2021) Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis. J Neurol Neurosurg Psychiatry 92:434\u2013443. https:\/\/doi.org\/10.1136\/jnnp-2020-323656","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR126","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000098965","volume":"58","author":"LV Laitinen","year":"1992","unstructured":"Laitinen LV, Bergenheim AT, Hariz MI (1992) Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereot Funct Neuros 58:14\u201321. https:\/\/doi.org\/10.1159\/000098965","journal-title":"Stereot Funct Neuros"},{"key":"12915_CR127","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/1531-8257(200003)15:2<230::aid-mds1005>3.0.co;2-u","volume":"15","author":"MS Baron","year":"2000","unstructured":"Baron MS, Vitek JL, Bakay RAE et al (2000) Treatment of advanced Parkinson\u2019s disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 15:230\u2013237. https:\/\/doi.org\/10.1002\/1531-8257(200003)15:2%3c230::aid-mds1005%3e3.0.co;2-u","journal-title":"Mov Disord"},{"key":"12915_CR128","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.surneu.2008.03.039","volume":"71","author":"AM Strutt","year":"2009","unstructured":"Strutt AM, Lai EC, Jankovic J et al (2009) Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson\u2019s disease. Surg Neurol 71:551\u2013558. https:\/\/doi.org\/10.1016\/j.surneu.2008.03.039","journal-title":"Surg Neurol"},{"key":"12915_CR129","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/mds.23155","volume":"25","author":"G Kleiner-Fisman","year":"2010","unstructured":"Kleiner-Fisman G, Lozano A, Moro E et al (2010) Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. Mov Disord 25:1496\u20131498. https:\/\/doi.org\/10.1002\/mds.23155","journal-title":"Mov Disord"},{"key":"12915_CR130","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/nejm200002173420703","volume":"342","author":"PR Schuurman","year":"2000","unstructured":"Schuurman PR, Bosch DA, Bossuyt PM et al (2000) A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 342:461\u2013468. https:\/\/doi.org\/10.1056\/nejm200002173420703","journal-title":"N Engl J Med"},{"key":"12915_CR131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord 32:283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disord"},{"key":"12915_CR132","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/s1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa\u2013foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/s1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"12915_CR133","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1468-1331.2011.03437.x","volume":"19","author":"AE Elia","year":"2012","unstructured":"Elia AE, Dollenz C, Soliveri P, Albanese A (2012) Motor features and response to oral levodopa in patients with Parkinson\u2019s disease under continuous dopaminergic infusion or deep brain stimulation. Eur J Neurol 19:76\u201383. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03437.x","journal-title":"Eur J Neurol"},{"key":"12915_CR134","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/mds.20237","volume":"19","author":"M Alegret","year":"2004","unstructured":"Alegret M, Valldeoriola F, Mart\u00ed M et al (2004) Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson\u2019s disease. Mov Disord 19:1463\u20131469. https:\/\/doi.org\/10.1002\/mds.20237","journal-title":"Mov Disord"},{"key":"12915_CR135","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3389\/fneur.2019.00934","volume":"10","author":"XD Liu","year":"2019","unstructured":"Liu XD, Bao Y, Liu G, jian, (2019) Comparison between levodopa\u2013carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol 10:934. https:\/\/doi.org\/10.3389\/fneur.2019.00934","journal-title":"Front Neurol"},{"key":"12915_CR136","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2016.05.015","volume":"29","author":"A Merola","year":"2016","unstructured":"Merola A, Espay AJ, Romagnolo A et al (2016) Advanced therapies in Parkinson\u2019s disease: long-term retrospective study. Park Relat Disord 29:104\u2013108. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.015","journal-title":"Park Relat Disord"},{"key":"12915_CR137","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","volume":"97","author":"M Rosebraugh","year":"2022","unstructured":"Rosebraugh M, Stodtmann S, Liu W, Facheris MF (2022) Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa\u2013carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat D 97:68\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.03.012","journal-title":"Parkinsonism Relat D"},{"key":"12915_CR138","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.25994","volume":"89","author":"F Cavallieri","year":"2021","unstructured":"Cavallieri F, Fraix V, Bove F et al (2021) Predictors of long-term outcome of subthalamic stimulation in Parkinson disease. Ann Neurol 89:587\u2013597. https:\/\/doi.org\/10.1002\/ana.25994","journal-title":"Ann Neurol"},{"key":"12915_CR139","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J et al (2022) European Academy of Neurology\/Movement Disorder Society-European section guideline on the treatment of Parkinson\u2019s disease: I. Invasive Ther Mov Disord 37:1360\u20131374. https:\/\/doi.org\/10.1002\/mds.29066","journal-title":"Invasive Ther Mov Disord"},{"key":"12915_CR140","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/jpm11080773","volume":"11","author":"V Leta","year":"2021","unstructured":"Leta V, Dafsari HS, Sauerbier A et al (2021) Personalised advanced therapies in Parkinson\u2019s disease: the role of non-motor symptoms profile. J Pers Med 11:773. https:\/\/doi.org\/10.3390\/jpm11080773","journal-title":"J Pers Med"},{"key":"12915_CR141","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s40263-022-00963-9","volume":"36","author":"A Antonini","year":"2022","unstructured":"Antonini A, Pahwa R, Odin P et al (2022) Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson\u2019s disease: a systematic review and bayesian network meta-analysis. CNS Drugs 36:1269\u20131283. https:\/\/doi.org\/10.1007\/s40263-022-00963-9","journal-title":"CNS Drugs"},{"key":"12915_CR142","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM et al (2021) Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol 90:52\u201361. https:\/\/doi.org\/10.1002\/ana.26073","journal-title":"Ann Neurol"},{"key":"12915_CR143","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"12915_CR144","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1093\/brain\/awz285","volume":"142","author":"JN Petry-Schmelzer","year":"2019","unstructured":"Petry-Schmelzer JN, Krause M, Dembek TA et al (2019) Non-motor outcomes depend on location of neurostimulation in Parkinson\u2019s disease. Brain 142:3592\u20133604. https:\/\/doi.org\/10.1093\/brain\/awz285","journal-title":"Brain"},{"key":"12915_CR145","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s1474-4422(22)00085-0","volume":"21","author":"VCD Cock","year":"2022","unstructured":"Cock VCD, Dodet P, Leu-Semenescu S et al (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 21:428\u2013437. https:\/\/doi.org\/10.1016\/s1474-4422(22)00085-0","journal-title":"Lancet Neurol"},{"key":"12915_CR146","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.parkreldis.2016.11.016","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Sringean J, Anan C et al (2016) Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson\u2019s disease using wearable sensors. Park Relat Disord 33:S36\u2013S41. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.016","journal-title":"Park Relat Disord"},{"key":"12915_CR147","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mdc3.13338","volume":"8","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2021","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Ares B et al (2021) Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Mov Disord Clin Pract 8:1216\u20131224. https:\/\/doi.org\/10.1002\/mdc3.13338","journal-title":"Mov Disord Clin Pract"},{"key":"12915_CR148","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","volume":"100","author":"I Reuter","year":"1999","unstructured":"Reuter I, Ellis CM, Chaudhuri KR (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson\u2019s disease and restless legs syndrome. Acta Neurol Scand 100:163\u2013167. https:\/\/doi.org\/10.1111\/j.1600-0404.1999.tb00732.x","journal-title":"Acta Neurol Scand"},{"key":"12915_CR149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","volume":"23","author":"RWK Borgemeester","year":"2016","unstructured":"Borgemeester RWK, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson\u2019s disease patients. Park Relat Disord 23:17\u201322. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.11.013","journal-title":"Park Relat Disord"},{"key":"12915_CR150","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mdc3.13239","volume":"8","author":"DG Standaert","year":"2021","unstructured":"Standaert DG, Aldred J, Anca-Herschkovitsch M et al (2021) DUOGLOBE: one-year outcomes in a real-world study of levodopa carbidopa intestinal gel for Parkinson\u2019s disease. Mov Disord Clin Pract 8:1061\u20131074. https:\/\/doi.org\/10.1002\/mdc3.13239","journal-title":"Mov Disord Clin Pract"},{"key":"12915_CR151","doi-asserted-by":"publisher","first-page":"1105650","DOI":"10.3389\/fneur.2023.1105650","volume":"14","author":"\u015e Diaconu","year":"2023","unstructured":"Diaconu \u015e, Irincu L, \u0162\u00een\u0163 D, Falup-Pecurariu C (2023) Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson\u2019s disease. Front Neurol 14:1105650. https:\/\/doi.org\/10.3389\/fneur.2023.1105650","journal-title":"Front Neurol"},{"key":"12915_CR152","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/mds.26564","volume":"31","author":"L Ricciardi","year":"2016","unstructured":"Ricciardi L, Bove F, Espay KJ et al (2016) 24-Hour infusion of levodopa\/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson\u2019s disease. Mov Disord 31:597\u2013598. https:\/\/doi.org\/10.1002\/mds.26564","journal-title":"Mov Disord"},{"key":"12915_CR153","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.parkreldis.2014.12.018","volume":"21","author":"H Abboud","year":"2015","unstructured":"Abboud H, Floden D, Thompson NR et al (2015) Impact of mild cognitive impairment on outcome following deep brain stimulation surgery for Parkinson\u2019s disease. Park Relat Disord 21:249\u2013253. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.018","journal-title":"Park Relat Disord"},{"key":"12915_CR154","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/brain\/123.10.2091","volume":"123","author":"JA Saint-Cyr","year":"2000","unstructured":"Saint-Cyr JA, Tr\u00e9panier LL, Kumar R et al (2000) Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson\u2019s disease. Brain 123:2091\u20132108. https:\/\/doi.org\/10.1093\/brain\/123.10.2091","journal-title":"Brain"},{"key":"12915_CR155","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s1474-4422(06)70475-6","volume":"5","author":"TD Parsons","year":"2006","unstructured":"Parsons TD, Rogers SA, Braaten AJ et al (2006) Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease: a meta-analysis. Lancet Neurol 5:578\u2013588. https:\/\/doi.org\/10.1016\/s1474-4422(06)70475-6","journal-title":"Lancet Neurol"},{"key":"12915_CR156","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/s1474-4422(08)70114-5","volume":"7","author":"K Witt","year":"2008","unstructured":"Witt K, Daniels C, Reiff J et al (2008) Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson\u2019s disease: a randomised, multicentre study. Lancet Neurol 7:605\u2013614. https:\/\/doi.org\/10.1016\/s1474-4422(08)70114-5","journal-title":"Lancet Neurol"},{"key":"12915_CR157","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/jnnp.2002.009803","volume":"75","author":"A Funkiewiez","year":"2004","unstructured":"Funkiewiez A, Ardouin C, Caputo E et al (2004) Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75:834. https:\/\/doi.org\/10.1136\/jnnp.2002.009803","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12915_CR158","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mdc3.13660","volume":"10","author":"CK Block","year":"2023","unstructured":"Block CK, Patel M, Risk BB et al (2023) Patients with cognitive impairment in Parkinson\u2019s disease benefit from deep brain stimulation: a case\u2013control study. Mov Disord Clin Pract 10:382\u2013391. https:\/\/doi.org\/10.1002\/mdc3.13660","journal-title":"Mov Disord Clin Pract"},{"key":"12915_CR159","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1586\/14737175.6.11.1695","volume":"6","author":"E Moro","year":"2006","unstructured":"Moro E, Lang AE (2006) Criteria for deep-brain stimulation in Parkinson\u2019s disease: review and analysis. Expert Rev Neurother 6:1695\u20131705. https:\/\/doi.org\/10.1586\/14737175.6.11.1695","journal-title":"Expert Rev Neurother"},{"key":"12915_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120339","volume":"440","author":"S Healy","year":"2022","unstructured":"Healy S, Shepherd H, Mooney N et al (2022) The effect of deep brain stimulation on impulse control related disorders in Parkinson\u2019s disease\u2014a 10-year retrospective study of 137 patients. J Neurol Sci 440:120339. https:\/\/doi.org\/10.1016\/j.jns.2022.120339","journal-title":"J Neurol Sci"},{"key":"12915_CR161","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","volume":"265","author":"MJ Catalan","year":"2018","unstructured":"Group O behalf of the ES, Catalan MJ, Molina-Arjona JA et al (2018) Improvement of impulse control disorders associated with levodopa\u2013carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. J Neurol 265:1279\u20131287. https:\/\/doi.org\/10.1007\/s00415-018-8803-1","journal-title":"J Neurol"},{"key":"12915_CR162","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","volume":"266","author":"L Lopiano","year":"2019","unstructured":"Lopiano L, Modugno N, Marano P et al (2019) Motor and non-motor outcomes in patients with advanced Parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study. J Neurol 266:2164\u20132176. https:\/\/doi.org\/10.1007\/s00415-019-09337-6","journal-title":"J Neurol"},{"key":"12915_CR163","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/wnf.0000000000000091","volume":"38","author":"A Todorova","year":"2015","unstructured":"Todorova A, Samuel M, Brown RG, Chaudhuri KR (2015) Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years\u2019 follow-up. Clin Neuropharmacol 38:132\u2013134. https:\/\/doi.org\/10.1097\/wnf.0000000000000091","journal-title":"Clin Neuropharmacol"},{"key":"12915_CR164","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.peptides.2011.07.020","volume":"32","author":"M Fujimiya","year":"2011","unstructured":"Fujimiya M, Ataka K, Asakawa A et al (2011) Ghrelin, des-acyl ghrelin and obestatin on the gastrointestinal motility. Peptides 32:2348\u20132351. https:\/\/doi.org\/10.1016\/j.peptides.2011.07.020","journal-title":"Peptides"},{"key":"12915_CR165","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1093\/brain\/awq221","volume":"133","author":"A Fasano","year":"2010","unstructured":"Fasano A, Romito LM, Daniele A et al (2010) Motor and cognitive outcome in patients with Parkinson\u2019s disease 8 years after subthalamic implants. Brain J Neurol 133:2664\u20132676. https:\/\/doi.org\/10.1093\/brain\/awq221","journal-title":"Brain J Neurol"},{"key":"12915_CR166","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-019-09184-5","volume":"266","author":"\u00c1 Sesar","year":"2019","unstructured":"Sesar \u00c1, Fern\u00e1ndez-Pajar\u00edn G, Ares B et al (2019) Continuous subcutaneous apomorphine in advanced Parkinson\u2019s disease patients treated with deep brain stimulation. J Neurol 266:659\u2013666. https:\/\/doi.org\/10.1007\/s00415-019-09184-5","journal-title":"J Neurol"},{"key":"12915_CR167","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/brainsci12030343","volume":"12","author":"D Georgiev","year":"2022","unstructured":"Georgiev D, Delali\u0107 S, Kri\u017enar NZ et al (2022) Switching and combining device-aided therapies in advanced Parkinson\u2019s disease: a double centre retrospective study. Brain Sci 12:343. https:\/\/doi.org\/10.3390\/brainsci12030343","journal-title":"Brain Sci"},{"key":"12915_CR168","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/wnf.0000000000000216","volume":"40","author":"I Regidor","year":"2017","unstructured":"Regidor I, Benita V, del de Pedro M\u00c1 et al (2017) Duodenal levodopa infusion for long-term deep brain stimulation-refractory symptoms in advanced Parkinson disease. Clin Neuropharmacol 40:103\u2013107. https:\/\/doi.org\/10.1097\/wnf.0000000000000216","journal-title":"Clin Neuropharmacol"},{"key":"12915_CR169","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/mds.27211","volume":"33","author":"N Kumar","year":"2018","unstructured":"Kumar N, Murgai A, Naranian T et al (2018) Levodopa\u2013carbidopa intestinal gel therapy after deep brain stimulation. Mov Disord 33:334\u2013335. https:\/\/doi.org\/10.1002\/mds.27211","journal-title":"Mov Disord"},{"key":"12915_CR170","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mdc3.13228","volume":"8","author":"I Boura","year":"2021","unstructured":"Boura I, Haliasos N, Giannopoulou \u0399 et al (2021) Combining device-aided therapies in Parkinson\u2019s disease: a case series and a literature review. Mov Disord Clin Pr 8:750\u2013757. https:\/\/doi.org\/10.1002\/mdc3.13228","journal-title":"Mov Disord Clin Pr"},{"key":"12915_CR171","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00415-016-8106-3","volume":"263","author":"S Drapier","year":"2016","unstructured":"Drapier S, Eusebio A, Degos B et al (2016) Quality of life in Parkinson\u2019s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol 263:1111\u20131119. https:\/\/doi.org\/10.1007\/s00415-016-8106-3","journal-title":"J Neurol"},{"key":"12915_CR172","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/219149","volume":"2015","author":"I Schlesinger","year":"2015","unstructured":"Schlesinger I, Eran A, Sinai A et al (2015) MRI guided focused ultrasound thalamotomy for moderate-to-severe tremor in Parkinson\u2019s disease. Park s Dis 2015:219149. https:\/\/doi.org\/10.1155\/2015\/219149","journal-title":"Park s Dis"},{"key":"12915_CR173","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3171\/2016.10.jns16758","volume":"128","author":"M Zaaroor","year":"2018","unstructured":"Zaaroor M, Sinai A, Goldsher D et al (2018) Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson\u2019s disease and essential tremor cases. J Neurosurg 128:202\u2013210. https:\/\/doi.org\/10.3171\/2016.10.jns16758","journal-title":"J Neurosurg"},{"key":"12915_CR174","doi-asserted-by":"publisher","first-page":"8207","DOI":"10.4081\/ni.2019.8207","volume":"11","author":"MA Pieroni","year":"2019","unstructured":"Pieroni MA (2019) Investigation of apomorphine during sleep in Parkinson\u2019s: improvement in UPDRS scores. Neurol Int 11:8207. https:\/\/doi.org\/10.4081\/ni.2019.8207","journal-title":"Neurol Int"},{"key":"12915_CR175","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/nejmoa035275","volume":"349","author":"P Krack","year":"2003","unstructured":"Krack P, Batir A, Blercom NV et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N Engl J Med 349:1925\u20131934. https:\/\/doi.org\/10.1056\/nejmoa035275","journal-title":"N Engl J Med"},{"key":"12915_CR176","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jns.2004.01.004","volume":"219","author":"M Krause","year":"2004","unstructured":"Krause M, Fogel W, Mayer P et al (2004) Chronic inhibition of the subthalamic nucleus in Parkinson\u2019s disease. J Neurol Sci 219:119\u2013124. https:\/\/doi.org\/10.1016\/j.jns.2004.01.004","journal-title":"J Neurol Sci"},{"key":"12915_CR177","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clineuro.2005.07.008","volume":"108","author":"JT Davis","year":"2006","unstructured":"Davis JT, Lyons KE, Pahwa R (2006) Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson\u2019s disease. Clin Neurol Neurosurg 108:461\u2013464. https:\/\/doi.org\/10.1016\/j.clineuro.2005.07.008","journal-title":"Clin Neurol Neurosurg"},{"key":"12915_CR178","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/02688697.2014.997665","volume":"29","author":"J Li","year":"2015","unstructured":"Li J, Zhang Y, Li Y (2015) Long-term follow-up of bilateral subthalamic nucleus stimulation in Chinese Parkinson\u2019s disease patients. Br J Neurosurg 29:329\u2013333. https:\/\/doi.org\/10.3109\/02688697.2014.997665","journal-title":"Br J Neurosurg"},{"key":"12915_CR179","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000500277","volume":"97","author":"R Kim","year":"2019","unstructured":"Kim R, Yoo D, Jung YJ et al (2019) Determinants of functional independence or its loss following subthalamic nucleus stimulation in Parkinson\u2019s disease. Stereotact Funct Neurosurg 97:106\u2013112. https:\/\/doi.org\/10.1159\/000500277","journal-title":"Stereotact Funct Neurosurg"},{"key":"12915_CR180","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/jpm12050718","volume":"12","author":"S Stankov\u00e1","year":"2022","unstructured":"Stankov\u00e1 S, Straka I, Ko\u0161utzk\u00e1 Z et al (2022) Levodopa-carbidopa intestinal gel improves symptoms of orthostatic hypotension in patients with Parkinson\u2019s disease\u2014prospective pilot interventional study. J Pers Med 12:718. https:\/\/doi.org\/10.3390\/jpm12050718","journal-title":"J Pers Med"},{"key":"12915_CR181","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/jpd-202278","volume":"11","author":"ST Jost","year":"2021","unstructured":"Group O behalf of E and the IP and MDSN-MPDS, Jost ST, Chaudhuri KR et al (2021) Subthalamic stimulation improves quality of sleep in Parkinson disease: a 36-month controlled study. J Park Dis 11:323\u2013335. https:\/\/doi.org\/10.3233\/jpd-202278","journal-title":"J Park Dis"},{"key":"12915_CR182","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.brs.2015.08.005","volume":"9","author":"HS Dafsari","year":"2016","unstructured":"Dafsari HS, Reddy P, Herchenbach C et al (2016) Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson\u2019s disease. Brain Stimul 9:78\u201385. https:\/\/doi.org\/10.1016\/j.brs.2015.08.005","journal-title":"Brain Stimul"},{"key":"12915_CR183","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3171\/jns.2006.104.4.502","volume":"104","author":"KE Lyons","year":"2006","unstructured":"Lyons KE, Pahwa R (2006) Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg 104:502\u2013505. https:\/\/doi.org\/10.3171\/jns.2006.104.4.502","journal-title":"J Neurosurg"},{"key":"12915_CR184","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.parkreldis.2009.05.006","volume":"16","author":"T van Laar","year":"2010","unstructured":"van Laar T, Postma AG, Drent M (2010) Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson\u2019s disease and pre-existing visual hallucinations. Park Relat Disord 16:71\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.05.006","journal-title":"Park Relat Disord"},{"key":"12915_CR185","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000107943","volume":"58","author":"M Zibetti","year":"2007","unstructured":"Zibetti M, Torre E, Cinquepalmi A et al (2007) Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 58:218\u2013223. https:\/\/doi.org\/10.1159\/000107943","journal-title":"Eur Neurol"},{"key":"12915_CR186","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/s0140-6736(88)90932-4","volume":"332","author":"TJ Christmas","year":"1988","unstructured":"Christmas TJ, Chapple CR, Lees AJ et al (1988) Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 332:1451\u20131453. https:\/\/doi.org\/10.1016\/s0140-6736(88)90932-4","journal-title":"Lancet"},{"key":"12915_CR187","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00702-015-1437-x","volume":"122","author":"A Storch","year":"2015","unstructured":"Group N-P Study, Storch A, Schneider CB et al (2015) Quantitative assessment of non-motor fluctuations in Parkinson\u2019s disease using the Non-Motor Symptoms Scale (NMSS). J Neural Transm 122:1673\u20131684. https:\/\/doi.org\/10.1007\/s00702-015-1437-x","journal-title":"J Neural Transm"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12915-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12915-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:42:56Z","timestamp":1742233376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12915-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":187,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12915"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12915-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.R. and T.K. are currently serving as president and vice-president of the German Deep Brain Stimulation Working Group (Arbeitsgemeinschaft Tiefe Hirnstimulation e.V.). R.R. received speaker honoraria from Abbot, Boston Scientifc, Esteve and Medtronic, received travel expenses from Boston Scientific, Esteve and Medtronic\u00a0and served as a consultant for Boston Scientific outside of this work. T.K. received speaker honoraria and research funding from Abbott, Medtronic and Abbvie. C.S. has received fees from serving on the scientific advisory board for Abbvie in the last 3\u00a0years, has received honoraria for speaking at conferences from Abbvie, Bial and Desitin in the last 3\u00a0years. L.T. serves as editor for Der Nervenarzt, serves as section editor for Neurological Research and Practice, and serves as editor for Cells, has received fees from serving on the scientific advisory board for Abbvie, Bial, Desitin, Stadapharm, Zambon in the last 3\u00a0years, has received fees for speaking at conferences from Abbvie, Bial, Desitin, Stadapharm, Zambon in the last 3\u00a0years. G.D. has served as a consultant for Boston Scientific, Cavion and Insightec. He receives royalties from Thieme publishers. He receives funding from the German Research Council (SFB 1261, T1) and private foundations. A.A.K. reports research grants from DFG (German Research Foundation)\u2014Project-ID 424778381\u2013 TRR 295 and under Germany\u00b4s Excellence Strategy\u2014EXC-2049-390688087, Lundbeck Foundation Grant Nr. R336-2020-1035). She also reports personal fees and travel grants by Medtronic, Boston Scientific and Stadapharm. P.K. reports research or educational grants from Swiss National Science Foundation (FNS 323530_177577\/FNS 32003BL_197709-1\/FNS 33IC30_198772), ROGER DE SPOELBERCH Foundation, Fondation Louis-Jeantet, Carigest, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, France Parkinson, Edmond Safra Philantropic Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J Fox Foundation, Aleva Neurotherapeutics, Boston Scientific, Medtronic, St. Jude Medical, GE Healthcare, Idorsia, UCB, all paid to employing institutions; lecturing fees to employing institution from Boston Scientific, Bial, Advisis; travel expenses to scientific meetings from Boston Scientific, Zambon, Abbvie, Merz Pharma (Schweiz) AG. A.Sch. has received lecture fees from Abbott, Novartis, Kyowa Kirin; has been serving as a consultant for Abbott, Zambon, Medtronic Inc; received royalties from Georg Thieme Verlag; received through his institution funding for his research from the German Research Council, Abbott, and the Brunhilde Moll Foundation. A.S. has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and the Helmholtz-Association outside the present study. He has received honoraria for presentations\/advisory boards\/consultations from Global Kinetics Corporation (manufacturer of the PKG\u00ae), Esteve, Desitin, Lobsor Pharmaceuticals, STADA, Bial, RG Gesellschaft, Zambon, NovoNordisk and AbbVie outside the present study. He has received royalties from Kohlhammer Verlag and Elsevier Press. He serves as an editorial board member of Stem Cells International. C.T. has received funding from BMBF (ERA Net) BRAVA-Project, and the M.J: Fox Foundation outside the present study. She has received honoraria for presentations\/advisory boards and consultations from Abbvie, STADA Pharm, UCB, Roche, Boehringer, Bial, Ono Pharm, Esteve, Convatec. She has received royalties from Thieme publisher and license fees from MAPI for PDSS-2. She serves on the editorial Board of Sleep Med and CNS Drugs, associate editor of NRP. G.U.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany\u2019s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy\u2014ID 390857198). He has ongoing research collaborations with Roche, UCB, AbbVie; served as a consultant for Abbvie, Alzprotect, Amylyx, Aprinoia, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva, UCB; received honoraria for scientific presentations from AbbVie, Bayer, Bial, Biogen, Bristol Myers Squibb, Esteve, Kyowa Kirin, Pfizer, Roche, Teva, UCB, Zambon; received publication royalties from Academic Press, Kohlhammer, and Thieme. All authors have contributed to, seen and approved the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"219"}}